Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells

Biochimica et Biophysica Acta - Biomembranes

Volumn 1788, Issue 5, 2009, Pages 911-917

  Seki, Satoru ^a   Kobayashi, Masaki ^a   Itagaki, Shirou ^a   Hirano, Takeshi ^a   Iseki, Ken ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

AIPT; Alveolar epithelial type II; Amiodarone; OATP2B1

Indexed keywords

AMIODARONE; CARRIER PROTEIN; ESTRONE SULFATE; MESSENGER RNA; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B3; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 2B1; SMALL INTERFERING RNA; SODIUM ION; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG INHIBITION; DRUG UPTAKE; ENZYME SPECIFICITY; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; LUNG TOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; BASE SEQUENCE; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; DNA PRIMERS; EPITHELIAL CELLS; HUMANS; KINETICS; ORGANIC ANION TRANSPORTERS; PULMONARY ALVEOLI; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 65249089205     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2009.03.003     Document Type: Article

References (48)

1. Herre J.M., Sauve M.J., Malone P., Griffin J.C., Helmy I., Langberg J.J., Goldberg H., and Scheinman M.M. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J. Am. Coll. Cardiol. 13 (1989) 442-449
2. Singh S.N., Fletcher R.D., Fisher S.G., Singh B.N., Lewis H.D., Deedwania P.C., Massie B.M., Colling C., and Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N. Eng. J. Med. 333 (1995) 77-82
3. Ceremuzynski L., Kleczar E., Krzeminska-Pakula M., Kuch J., Nartowicz E., Smielak-Koromble J., Dyduszynski A., Maciejewicz J., Zaleska T., Lazarczyk-Kedzia E., Motyka J., Paczkowska B., Sczaniecka O., and Yusuf S. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J. Am. Coll. Cardiol. 20 (1992) 1056-1062
4. Doval H.C., Nul D.R., Grancelli H.O., Perrone S.V., Bortman G.R., and Curiel R. Randomized trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 344 (1994) 493-498
5. Janse M.J., Malik M., Camm A.J., Julian D.G., Frangin G.A., and Schwartz P.J. Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). Eur. Heart J. 19 (1998) 85-95
6. Pfisterer M., Kiowski W., Burckhardt D., Follath F., and Burkhart F. Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am. J. Cardiol. 69 (1992) 1399-1402
7. Singh S.N., Fisher S.G., Deedwania P.C., Rohatgi P., Singh B.N., and Fletcher R.D. Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). J. Am. Coll. Cardiol. 30 (1997) 514-517
8. Hondeghem L.M., and Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 81 (1990) 686-690
9. Connolly S.J. Evidence-based analysis of amiodarone efficacy and safety. Circulation 100 (1999) 2025-2034
10. Mason J.W. Amiodarone. N. Engl. J. Med. 316 (1987) 455-466
11. Sunderji R., Kanji Z., and Gin K. Pulmonary effects of low dose amiodarone: a review of the risks and recommendations for surveillance. Can. J. Cardiol. 16 (2000) 1435-1440
12. Blake T.L., and Reasor M.J. Acute pulmonary inflammation in hamsters following intratracheal administration of amiodarone. Inflammation 19 (1995) 55-65
13. Chatelain P., Laruel R., Vic P., and Brotelle R. Differential effects of amiodarone and propranolol on lipid dynamics and enzymatic activities in cardiac sarcolemmal membranes. Biochem. Pharmacol. 38 (1989) 1231-1239
14. Massey T.E., Leeder R.G., Rafeiro E., and Brien J.F. Mechanisms in the pathogenesis of amiodarone-induced pulmonary toxicity. Can. J. Physiol. Pharmacol. 73 (1995) 1675-1685
15. Choi I.S., Kim B.S., Cho K.S., Park J.C., Jang M.H., Shin M.C., Jung S.B., Chung J.H., and Kim C.J. Amiodarone induces apoptosis in L-132 human lung epithelial cell line. Toxicol. Lett. 132 (2002) 47-55
16. Bolt M.W., Card J.W., Racz W.J., Brien J.F., and Massey T.E. Disruption of mitochondrial function and cellular ATP levels by amiodarone and N-desethylamiodarone in initiation of amiodarone-induced pulmonary cytotoxicity. J. Pharmacol. Exp. Ther. 298 (2001) 1280-1289
17. Adams P.C., Holt D.W., Storey G.C., Morley A.R., Callaghan J., and Campbell R.W. Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation 72 (1985) 1064-1075
18. Brien J.F., Jimmo S., Brennan F.J., Ford S.E., and Armstrong P.W. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can. J. Physiol. Pharmacol. 65 (1987) 360-364
19. Plomp T.A., Wiersinga W.M., and Maes R.A. Tissue distribution of amiodarone and desethylamiodaone in rats after multiple intraperitoneal administration of various amiodarone dosages. Arzneimittelforschung 35 (1985) 122-129
20. Plomp T.A., Wiersinga W.M., and Maes R.A. Tissue distribution of amiodarone and desethylamiodaone in rats after repeated oral administration of various amiodarone dosages. Arzneimittelforschung 35 (1985) 1805-1810
21. Martín-Algarra R.V., Pascual-Costa R.M., Merino M., and Casabó V.G. Intestinal absorption kinetics of amiodarone in rat small intestine. Biopharm. Drug Dispos. 18 (1997) 523-532
22. Kakumoto M., Takara K., Sakaeda T., Tanigawara Y., Kita T., and Okumura K. MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. Biol. Pharm. Bull. 25 (2002) 1604-1607
23. Kodawara T., Masuda S., Wakasugi H., Uwai Y., Futami T., Saito H., Abe T., and Inui K. Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm. Res. 19 (2002) 738-743
24. Funakoshi S., Murakami T., Yumoto R., Kiribayashi Y., and Takano M. Role of organic anion transporting polypeptide 2 in pharmacokinetics of digoxin and beta-methyldigoxin in rats. J. Pharm. Sci. 94 (2005) 1196-1203
25. Kobayashi M., Fujita I., Itagaki S., Hirano T., and Iseki K. Transport mechanism for l-lactic acid in human myocytes using human prototypic embryonal rhabdomyosarcoma cell line (RD cells). Biol. Pharm. Bull. 28 (2005) 1197-1201
26. Ballestero M.R., Monte M.J., Briz O., Jimenez F., Gonzalez-San Martin F., and Marin J.J. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem. Pharmacol. 72 (2006) 729-738
27. Sai Y., Kaneko Y., Ito S., Mitsuoka K., Kato Y., Tamai I., Artursson P., and Tsuji A. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab. Dispos. 34 (2006) 1423-1431
28. Tamai I., Nezu J., Uchino H., Sai Y., Oku A., Shimane M., and Tsuji A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273 (2000) 251-260
29. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
30. Nozawa T., Imai K., Nezu J., Tsuji A., and Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. 308 (2004) 438-445
31. Marchlinski F.E., Gansler T.S., Waxman H.L., and Josephson M.E. Amiodarone pulmonary toxicity. Ann. Intern. Med. 97 (1982) 839-845
32. Martin W.J., and Rosenow E.C. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest 93 (1988) 1242-1248
33. Pitcher W.D. Amiodarone pulmonary toxicity. Am. J. Med. Sci. 303 (1992) 206-212
34. Uhal B.D. Cell cycle kinetics in the alveolar epithelium. Am. J. Physiol. Lung Cell. Mol. Physiol. 272 (1997) 1031-1045
35. Witschi H. Responses of the lung to toxic injury. Environ. Health Perspect. 85 (1990) 5-13
36. Hagenbuch B., and Meier P.J. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447 (2004) 653-665
37. Hagenbuch B., and Meier P.J. The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609 (2003) 1-18
38. König J., Seithel A., Gradhand U., and Fromm M.F. Pharmacogenomics of human OATP transporters, Naunyn. Schmiedebergs. Arch. Pharmacol. 372 (2006) 432-443
39. Hagenbuch B. Cellular entry of thyroid hormones by organic anion transporting polypeptides. Best Pract. Res. Clin. Endocrinol. Metab. 21 (2007) 209-221
40. Kullak-Ublick G.A., Ismair M.G., Stieger B., Landmann L., Huber R., Pizzagalli F., Fattinger K., Meier P.J., and Hagenbuch B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120 (2001) 525-533
41. Tamai I., Nozawa T., Koshida M., Nezu J., Sai Y., and Tsuji A. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm. Res. 18 (2001) 1262-1269
42. Nishimura T., Kubo Y., Kato Y., Sai Y., Ogihara T., and Tsuji A. Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: involvement of organic anion transporting polypeptide (OATP)-B. Pharm. Res. 24 (2007) 90-98
43. Bossuyt X., Müller M., Hagenbuch B., and Meier P.J. Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J. Pharmacol. Exp. Ther. 276 (1996) 891-896
44. Holt D.W., Tucker G.T., Jackson P.R., and Storey G.C. Amiodarone pharmacokinetics. Am. Heart J. 106 (1983) 840-847
45. Nozawa T., Nakajima M., Tamai I., Noda K., Nezu J., Sai Y., Tsuji A., and Yokoi T. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302 (2002) 804-813
46. Shimizu M., Fuse K., Okudaira K., Nishigaki R., Maeda K., Kusuhara H., and Sugiyama Y. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 33 (2005) 1477-1481
47. Grube M., Köck K., Oswald S., Draber K., Meissner K., Eckel L., Böhm M., Felix S.B., Vogelgesang S., Jedlitschky G., Siegmund W., Warzok R., and Kroemer H.K. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther. 80 (2006) 607-620
48. Kopplow K., Letschert K., König J., Walter B., and Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol. 68 (2005) 1031-1038